Payment overview · 2025
General Payments
$297.83
14 reported records · 9 companies
Healthcare provider profile · identity verified
James Wesley Campbell, DO
Allopathic & Osteopathic Physicians|Pediatrics · NORTON, VA · NPI 1629128640
Verified facts
What the public records show
CMS Open Payments records show James Wesley Campbell, DO received $297.83 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.10 | 25.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.08 | 20.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.88 | 16.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.88 | 8.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.07 | 7.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.66 | 6.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.66 | 5.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.41 | 5.2% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.09 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $297.83 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.89 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.89 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.08 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.88 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 576 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 119 |
| Losartan Potassium | Losartan Potassium | 425 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 424 | 94 |
| Lisinopril | Lisinopril | 419 | 100 |
| Gabapentin | Gabapentin | 370 | 59 |
| Furosemide | Furosemide | 327 | 76 |
| Omeprazole | Omeprazole | 315 | 78 |
| Potassium Chloride | Potassium Chloride | 286 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 53 |
| Metformin Hcl | Metformin Hcl | 236 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 227 | 62 |
| Carvedilol | Carvedilol | 220 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 48 |
| Trazodone Hcl | Trazodone Hcl | 203 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 43 |
| Clonazepam | Clonazepam | 192 | 23 |
| Famotidine | Famotidine | 180 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 173 | 31 |
| Prednisone | Prednisone | 173 | 118 |
| Montelukast Sodium | Montelukast Sodium | 170 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 141 | 31 |
| Eliquis | Apixaban | 135 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 120 | 30 |
| Meloxicam | Meloxicam | 118 | 24 |
| Tramadol Hcl | Tramadol Hcl | 118 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 36 |
| Azithromycin | Azithromycin | 112 | 78 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 19 |
| Ozempic | Semaglutide | 95 | 16 |
| Ondansetron Odt | Ondansetron | 91 | 34 |
| Januvia | Sitagliptin Phosphate | 90 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 28 |
| Simvastatin | Simvastatin | 88 | 23 |
| Allopurinol | Allopurinol | 85 | 21 |
| Temazepam | Temazepam | 84 | 11 |
| Ibuprofen | Ibuprofen | 83 | 22 |
| Lorazepam | Lorazepam | 77 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 77 | 14 |
| Farxiga | Dapagliflozin Propanediol | 75 | 22 |
| Alendronate Sodium | Alendronate Sodium | 72 | 20 |
| Mirtazapine | Mirtazapine | 71 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 69 | 14 |
| Alprazolam | Alprazolam | 68 | suppressed |
| Dutasteride | Dutasteride | 68 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 16 |
| Clonidine Hcl | Clonidine Hcl | 61 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 15 |
| Buspirone Hcl | Buspirone Hcl | 59 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 13 |
| Sertraline Hcl | Sertraline Hcl | 59 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 58 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 14 |
| Metformin Hcl Er | Metformin Hcl | 57 | 15 |
| Bupropion Xl | Bupropion Hcl | 55 | suppressed |
| Celecoxib | Celecoxib | 55 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | suppressed |
| Spironolactone | Spironolactone | 54 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Glipizide | Glipizide | 47 | 12 |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 45 | 14 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Finasteride | Finasteride | 42 | 11 |
| Glipizide Er | Glipizide | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Atenolol | Atenolol | 40 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 14 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | 11 |
| Topiramate | Topiramate | 37 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 25 |
| Mupirocin | Mupirocin | 32 | 18 |
| Nitroglycerin | Nitroglycerin | 32 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Dilantin | Phenytoin | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 12 |
| Sucralfate | Sucralfate | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 23 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Repatha Syringe | Evolocumab | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Ibu | Ibuprofen | 20 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 20 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 14 |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Klor-Con M10 | Potassium Chloride | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Estazolam | Estazolam | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $297.83 · 14 records | Novo Nordisk Inc | AREXVY, CAPLYTA, Cologuard Collection Kit, Jornay PM, MOUNJARO, Ozempic, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, VOQUEZNA, VYEPTI, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error